You are here

  • Home
  • Archive
  • Volume 11, Issue 1
  • Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflamma…

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation

 

Online download statistics by month:

Online download statistics by month: January 2023 to September 2025

AbstractFullPdf
Jan 202311191128163
Feb 2023713727197
Mar 2023329335126
Apr 2023244246100
May 202321822891
Jun 202322522690
Jul 202321221896
Aug 202322722758
Sep 202317017176
Oct 202315215250
Nov 202321421467
Dec 202313513671
Jan 2024195195148
Feb 2024154154100
Mar 2024256258224
Apr 2024168168133
May 202414114490
Jun 2024164165108
Jul 2024165164126
Aug 202412512883
Sep 2024147147105
Oct 2024190190125
Nov 2024207212124
Dec 2024267273163
Jan 2025201208142
Feb 2025325327147
Mar 2025151153106
Apr 2025246246169
May 2025198199131
Jun 202514214399
Jul 2025220
Aug 2025110
Sep 2025220
Total740574873508